Surmodics, Inc. (NASDAQ:SRDX) Shares Sold by Disciplined Growth Investors Inc. MN

Disciplined Growth Investors Inc. MN trimmed its position in shares of Surmodics, Inc. (NASDAQ:SRDX - Free Report) by 11.9% in the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 580,566 shares of the company's stock after selling 78,609 shares during the quarter. Disciplined Growth Investors Inc. MN owned approximately 4.07% of Surmodics worth $24,407,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently added to or reduced their stakes in the company. Gabelli Funds LLC boosted its stake in Surmodics by 393.7% during the 2nd quarter. Gabelli Funds LLC now owns 260,200 shares of the company's stock worth $10,939,000 after purchasing an additional 207,500 shares during the last quarter. Gardner Lewis Asset Management L P purchased a new stake in Surmodics during the 2nd quarter valued at about $8,531,000. Nisa Investment Advisors LLC raised its holdings in Surmodics by 4,722.3% in the 2nd quarter. Nisa Investment Advisors LLC now owns 68,429 shares of the company's stock valued at $2,877,000 after acquiring an additional 67,010 shares during the last quarter. Versor Investments LP acquired a new stake in Surmodics in the 2nd quarter valued at about $2,723,000. Finally, Sagefield Capital LP purchased a new position in Surmodics in the 2nd quarter worth approximately $2,350,000. 96.63% of the stock is owned by institutional investors and hedge funds.

Surmodics Trading Up 0.1 %

Surmodics stock traded up $0.02 during mid-day trading on Friday, hitting $38.49. The company's stock had a trading volume of 62,279 shares, compared to its average volume of 232,385. Surmodics, Inc. has a 1 year low of $25.17 and a 1 year high of $42.44. The company has a current ratio of 3.98, a quick ratio of 3.22 and a debt-to-equity ratio of 0.25. The firm has a market capitalization of $548.87 million, a PE ratio of 40.52 and a beta of 1.20. The stock's fifty day moving average is $40.03 and its two-hundred day moving average is $36.54.

Surmodics (NASDAQ:SRDX - Get Free Report) last issued its quarterly earnings data on Wednesday, July 31st. The company reported ($0.27) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.31) by $0.04. Surmodics had a positive return on equity of 3.88% and a negative net margin of 1.16%. The firm had revenue of $30.34 million during the quarter, compared to the consensus estimate of $30.32 million. On average, analysts anticipate that Surmodics, Inc. will post -0.47 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research firms recently commented on SRDX. StockNews.com started coverage on Surmodics in a report on Saturday. They issued a "hold" rating for the company. Needham & Company LLC reaffirmed a "hold" rating on shares of Surmodics in a research note on Monday, August 5th. Five investment analysts have rated the stock with a hold rating, According to data from MarketBeat, Surmodics presently has an average rating of "Hold" and an average price target of $50.00.

Surmodics Profile

Surmodics, Inc, together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD).